Zobrazeno 1 - 10
of 23
pro vyhledávání: '"David R Liljenquist"'
Autor:
Sandra M. Lord, Henry T. Bahnson, Carla J. Greenbaum, David R. Liljenquist, John Virostko, Cate Speake
Publikováno v:
PLoS ONE, Vol 18, Iss 12 (2023)
Externí odkaz:
https://doaj.org/article/579ab574b1ac43e2a2376a6be0c40d62
Autor:
Shridhara Alva, Ronald Brazg, Kristin Castorino, Mark Kipnes, David R. Liljenquist, Hanqing Liu
Publikováno v:
Diabetes Therapy. 14:767-776
Autor:
Satish K, Garg, George, Grunberger, Ruth, Weinstock, Margaret L, Lawson, Irl B, Hirsch, Linda A, DiMeglio, Rodica, Pop-Busui, Athena, Philis-Tsimikas, Mark, Kipnes, David R, Liljenquist, Ronald L, Brazg, Yogish C, Kudva, Bruce A, Buckingham, Janet B, McGill, Anders L, Carlson, Amy B, Criego, Mark P, Christiansen, Kevin B, Kaiserman, Kurt J, Griffin, Greg P, Forlenza, Bruce W, Bode, Robert H, Slover, Ashleigh, Keiter, Chenxiao, Ling, Briggitte, Marinos, Toni L, Cordero, John, Shin, Scott W, Lee, Andrew S, Rhinehart, Robert A, Vigersky, Mary, Jane Clifton
Publikováno v:
Diabetes Technology & Therapeutics. 25:1-12
Autor:
Gregory P. Forlenza, Laya Ekhlaspour, Linda A. DiMeglio, Larry A. Fox, Henry Rodriguez, Dorothy I. Shulman, Kevin B. Kaiserman, David R. Liljenquist, John Shin, Scott W. Lee, Bruce A. Buckingham
Publikováno v:
Pediatric Diabetes. 23:324-329
Highly variable insulin sensitivity, susceptibility to hypoglycemia and inability to effectively communicate hypoglycemic symptoms pose significant challenges for young children with type 1 diabetes (T1D). Herein, outcomes during clinical MiniMed™
Autor:
BRUCE W. BODE, TIMOTHY S. BAILEY, KRISTIN N. CASTORINO, MARK P. CHRISTIANSEN, SATISH K. GARG, KEVIN B. KAISERMAN, DAVID R. LILJENQUIST, DOROTHY I. SHULMAN, ROBERT H. SLOVER, JOHN SHIN, FEN PENG, SUIYING HUANG, ANDREW S. RHINEHART, ROBERT A. VIGERSKY
Publikováno v:
Diabetes. 71
Objective: A CGM sensor that is disposable and requires no calibration may make glucose management easier for people living with diabetes. The present study reports on the interim analysis of a new disposable zero-calibration sensor in adults and you
Autor:
ROBERT A. VIGERSKY, BRUCE W. BODE, RONALD L. BRAZG, BRUCE A. BUCKINGHAM, ANDERS L. CARLSON, KEVIN B. KAISERMAN, MARK KIPNES, DAVID R. LILJENQUIST, ATHENA PHILIS-TSIMIKAS, CATHERINE PIHOKER, RODICA POP-BUSUI, JOHN REED, JENNIFER SHERR, DOROTHY I. SHULMAN, ROBERT H. SLOVER, JAMES THRASHER, XIAOXIAO CHEN, MARGARET LIU, TONI L. CORDERO, MELISSA VELLA, ANDREW S. RHINEHART, JOHN SHIN
Publikováno v:
Diabetes. 71
Background: Safety and effectiveness outcomes of individuals using the MiniMed™ 780G system with the no-calibration Guardian™ 4 sensor during the first three months of use were analyzed. Methods: Participants (N=176, aged 7-75 years) with T1D use
Autor:
SHRIDHARA A. KARINKA, RONALD L. BRAZG, KRISTIN N. CASTORINO, DAVID R. LILJENQUIST, MARK KIPNES, HANQING LIU
Publikováno v:
Diabetes. 71
FreeStyle Libre 3 is the next generation FreeStyle Libre system with the same sensor tail but an on-body component that is about 70% smaller than Libre 2. We evaluated the accuracy of the FreeStyle Libre 3 system in people with diabetes ages 4 years
Autor:
Gregory P. Forlenza, Laya Ekhlaspour, Linda A. DiMeglio, Larry A. Fox, Henry Rodriguez, Dorothy I. Shulman, Kevin B. Kaiserman, David R. Liljenquist, John Shin, Scott W. Lee, Bruce A. Buckingham
Publikováno v:
Pediatric Diabetes. 23
Autor:
Mark P. Christiansen, Timothy S. Bailey, Anna R Chang, David R. Liljenquist, Katherine S. Tweden, Francine R. Kaufman, Bruce W. Bode, Ronald L. Brazg, Andrew Dehennis, Halis Kaan Akturk, Satish K. Garg, Douglas S Denham
Publikováno v:
Diabetes Technology & Therapeutics
Background: Use of continuous glucose monitoring (CGM) systems is being rapidly adopted as standard of care for insulin-requiring patients with diabetes. The PROMISE study (NCT03808376) evaluated the accuracy and safety of the next-generation implant
Autor:
David R. Liljenquist, Timothy S. Bailey, Francine R. Kaufman, Mark P. Christiansen, Satish K. Garg, Halis Kaan Akturk, Douglas S Denham, Andrew Dehennis, Bruce W. Bode, Katherine S. Tweden, Ronald L. Brazg, Anna Chang
Publikováno v:
Diabetes. 70
Background: The prospective, multi-center PROMISE study evaluated the safety and accuracy of the next generation Eversense CGM System for up to 180 days in 181 adults with diabetes at 8 US clinical sites. Methods: Accuracy was evaluated by comparing